Pathologic complete response (pCR) to preoperative sequential doxorubicin/cyclophosphamide (AC) and taxane (AC-T) or AC followed by paclitaxel and trastuzumab (AC-TH) in stage II-III HER2-positive breast cancer

被引：0
|
作者：
Chumsri, S.
Jeter, S. C.
Jacobs, L. K.
Lange, J. R.
Davidson, N. E.
Emens, L. A.
Fetting, J. H.
Gabrielson, E.
Zhang, Z.
Stearns, V.
机构：
[1] Univ Maryland, Med Ctr, Baltimore, MD 21201 USA
[2] Kimmel Canc Ctr Johns Hopkins, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.11521
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11521
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Pathologic Complete Response to Preoperative Sequential Doxorubicin/Cyclophosphamide and Single-Agent Taxane With or Without Trastuzumab in Stage II/III HER2-Positive Breast Cancer
    Chumsri, Saranya
    Jeter, Stacie
    Jacobs, Lisa K.
    Nassar, Hind
    Armstrong, Deborah K.
    Emens, Leisha A.
    Fetting, John H.
    Lange, Julie R.
    Riley, Carol
    Tsangaris, Theodore N.
    Wolff, Antonio C.
    Zellars, Richard
    Zhang, Zhe
    Stearns, Vered
    [J]. CLINICAL BREAST CANCER, 2010, 10 (01) : 40 - 45
  • [2] Docetaxel, carboplatin and trastuzumab (TCH) and doxorubicin/cyclophosphamide followed by docetaxel/trastuzumab (AC-TH) produce superior disease-free survival (DFS) compared to AC-T in patients (pts) with HER-2 positive early breast cancer (EBC), with increased cardiac toxicity confined to AC-TH: BCIRG 006 study
    不详
    [J]. EJC SUPPLEMENTS, 2006, 4 (02): : 108 - 109
  • [3] Neoadjuvant dose dense chemotherapy (NDDC) with sequential doxorubicin/cyclophosphamide (AC) followed by taxane yields high pathologic complete response (pCR) rate in stage II/III breast cancer.
    Schwartzberg, LS
    Kanter, LR
    Huang, R
    Tauer, KW
    Somer, BR
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S227 - S228
  • [4] Efficacy results of node-negative HER2-amplified breast cancer subset from BCIRG 006 study: A phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin, and trastuzumab (TCH).
    Valero, V.
    Slamon, D. J.
    Eiermann, W.
    Robert, N. J.
    Pienkowski, T.
    Martin, M.
    Mackey, J. R.
    Lindsay, M. A.
    Bee-Munteanu, V.
    Press, M. F.
    Sauter, G.
    Crown, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC®T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients:: BCIRG 006 study
    Slamon, D
    Eiermann, W
    Robert, N
    Pienkowski, T
    Martin, M
    Pawlicki, M
    Chan, A
    Smylie, M
    Liu, M
    Falkson, C
    Pinter, T
    Fornander, T
    Shiftan, T
    Valero, V
    Von Minckwitz, G
    Mackey, J
    Tabah-Fisch, J
    Buyse, M
    Lindsay, MA
    Riva, A
    Bee, V
    Pegram, M
    Press, M
    Crown, J
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S5 - S5
  • [6] Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.
    Slamon, D.
    Eiermann, W.
    Robert, N.
    Pienkowski, T.
    Martin, M.
    Rolski, J.
    Chan, A.
    Mackey, J.
    Liu, M.
    Pinter, T.
    Valero, V.
    Falkson, C.
    Fornander, T.
    Shiftan, T.
    Olsen, S.
    Buyse, M.
    Kiskartalyi, T.
    Landreau, V
    Wilson, V
    Press, M.
    Crown, J.
    [J]. CANCER RESEARCH, 2009, 69 (24) : 500S - 500S
  • [7] Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience
    Singh, Jasmeet C.
    Mamtani, Anita
    Barrio, Andrea
    Morrow, Monica
    Sugarman, Steven
    Jones, Lee W.
    Yu, Anthony F.
    Argolo, Daniel
    Smyth, Lilian M.
    Modi, Shanu
    Schweber, Sarah
    Boafo, Camilla
    Patil, Sujata
    Norton, Larry
    Baselga, Jose
    Hudis, Clifford A.
    Dang, Chau
    [J]. ONCOLOGIST, 2017, 22 (02): : 139 - 143
  • [8] Pathologic complete response rate with doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-positive early stage breast cancer: A single institution experience
    Singh, J. C.
    Sugarman, S.
    Jones, L.
    Boafo, C.
    Patil, S.
    Schweber, S.
    Yu, A.
    Argolo, D.
    Modi, S.
    Iyengar, N.
    Smyth, L.
    Norton, L.
    Baselga, J.
    Hudis, C.
    Dang, C.
    [J]. CANCER RESEARCH, 2016, 76
  • [9] Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+early breast cancer
    Slamon, D. J.
    Eiermann, W.
    Robert, N. J.
    Giermek, J.
    Martin, M.
    Jasiowka, M.
    Mackey, J. R.
    Chan, A.
    Liu, M-C
    Pinter, T.
    Valero, V.
    Falkson, C.
    Fornander, T.
    Shiftan, T. A.
    Bensfia, S.
    Hitler, S.
    Xu, N.
    Bee-Munteanu, V.
    Drevot, P.
    Press, M. F.
    Crown, J.
    [J]. CANCER RESEARCH, 2016, 76
  • [10] Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study
    Burstein, HJ
    Harris, LN
    Gelman, R
    Lester, SC
    Nunes, RA
    Kaelin, CM
    Parker, LM
    Ellisen, LW
    Kuter, I
    Gadd, MA
    Christian, RL
    Kennedy, PR
    Borges, VF
    Bunnell, CA
    Younger, J
    Smith, BL
    Winer, EP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) : 46 - 53
12345